Oncotarget

Research Perspectives:

Neddylation and anti-tumor immunity

Xiaoguang Wang, Scott Best and Alexey V. Danilov _

PDF  |  Full Text  |  How to cite

Oncotarget. 2021; 12:2227-2230. https://doi.org/10.18632/oncotarget.28019

Metrics: PDF 1191 views  |   Full Text 3174 views  |   ?  


Abstract

Xiaoguang Wang1, Scott Best2 and Alexey V. Danilov1

1 Department of Hematology and Hematopoietic Stem Cell Transplant, City of Hope National Medical Center, Duarte, CA, USA

2 Molecular and Cellular Biology, University of Washington, Seattle, WA, USA

Correspondence to:

Alexey V. Danilov, email: [email protected]

Keywords: neddylation; T cell; pevonedistat

Received: June 10, 2021     Accepted: June 21, 2021     Published: October 12, 2021

Copyright: © 2021 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Contrary to chemotherapy, novel targeted therapies are associated with diverse immunomodulatory effects. Nedd8 is a small ubiquitin-like modifier that is involved in regulation of protein degradation. Neddylation is a promising target in cancer. Pevonedistat, a small molecule inhibitor of the Nedd8-activating enzyme, demonstrates pre-clinical activity in multiple tumor types. Recent studies have revealed that neddylation is important in immunity. We and others have shown that interfering with neddylation causes downstream immunomodulatory effects potentially leading to enhanced anti-tumor immunity. Thus, Nedd8 is a promising target in immuno-oncology.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28019